nach oben

Current Osteoporosis Reports

Erschienen in:

23.03.2019 | Cancer-induced Musculoskeletal Diseases (E Keller and J Sterling, Section editors)

MicroRNAs in Bone Metastasis

verfasst von: Eric Hesse, Hanna Taipaleenmäki

Erschienen in: Current Osteoporosis Reports | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review provides an update on the recent literature describing the role of microRNAs (miRNAs) in cancer formation and bone metastasis. We confined our focus on osteosarcoma, breast cancer, prostate cancer, and epithelial-mesenchymal transition.

Recent Findings

In all areas covered, major discoveries on the role of miRNAs in tumorigenesis and metastasis have been made. Novel signaling networks were identified with miRNAs having a central function. Potential improvements in the diagnosis of malignant diseases and the long-term follow-up might become possible by the use of miRNAs. Furthermore, miRNAs also have disease-modifying properties and might emerge as a new class of therapeutic molecules.

Summary

MiRNAs are novel and important regulators of multiple cellular and molecular events. Due to their functions, miRNAs might become useful to improve the diagnosis, follow-up and treatment of cancer, and metastases. Thus, miRNAs are molecules of great interest in translational medicine.

Michlewski G, Cáceres JF. Post-transcriptional control of miRNA biogenesis. RNA. 2019;25:1–16. https://doi.org/10.1261/rna.068692.118.CrossRefPubMedPubMedCentral

Dragomir M, Mafra A, Dias S, Vasilescu C, Calin G. Using microRNA networks to understand cancer. Int J Mol Sci. 2018;19:1871. https://doi.org/10.3390/ijms19071871.CrossRefPubMedCentral

Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2018;234:5451–65. https://doi.org/10.1002/jcp.27486.CrossRefPubMed

Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11:145–56. https://doi.org/10.1038/nrclinonc.2014.5.CrossRefPubMed

Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs — an update. Nat Rev Clin Oncol. 2018;15:541–63. https://doi.org/10.1038/s41571-018-0035-x.CrossRefPubMed

Kim YH, Goh TS, Lee C-S, Oh SO, Il Kim J, Jeung SH, et al. Prognostic value of microRNAs in osteosarcoma: a meta-analysis. Oncotarget. 2017;8:8726–37. https://doi.org/10.18632/oncotarget.14429.CrossRefPubMedPubMedCentral

Wang C, Jing J, Cheng L. Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma. Investig New Drugs. 2018;36:1116–32. https://doi.org/10.1007/s10637-018-0624-7.CrossRef

Khordadmehr M, Shahbazi R, Ezzati H, Jigari-Asl F, Sadreddini S, Baradaran B. Key microRNAs in the biology of breast cancer; emerging evidence in the last decade. J Cell Physiol. 2018. https://doi.org/10.1002/jcp.27716.

Shajari E, Mollasalehi H. Ribonucleic-acid-biomarker candidates for early-phase group detection of common cancers. Genomics. 2018. https://doi.org/10.1016/j.ygeno.2018.08.011.

10.

Mandujano-Tinoco EA, García-Venzor A, Melendez-Zajgla J, Maldonado V. New emerging roles of microRNAs in breast cancer. Breast Cancer Res Treat. 2018;171:247–59. https://doi.org/10.1007/s10549-018-4850-7.CrossRefPubMed

11.

Song C-J, Chen H, Chen L-Z, Ru G-M, Guo J-J, Ding Q-N. The potential of microRNAs as human prostate cancer biomarkers: a meta-analysis of related studies. J Cell Biochem. 2018;119:2763–86. https://doi.org/10.1002/jcb.26445.CrossRefPubMed

12.

Varshney J, Subramanian S. MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics. Front Mol Biosci. 2015;2:31. https://doi.org/10.3389/fmolb.2015.00031.CrossRefPubMedPubMedCentral

13.

Imani S, Wu R-C, Fu J. MicroRNA-34 family in breast cancer: from research to therapeutic potential. J Cancer. 2018;9:3765–75. https://doi.org/10.7150/jca.25576.CrossRefPubMedPubMedCentral

14.

Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma — connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017;13:480–91. https://doi.org/10.1038/nrendo.2017.16.CrossRefPubMed

15.

Zhang Y, Yang J, Zhao N, Wang C, Kamar S, Zhou Y, et al. Progress in the chemotherapeutic treatment of osteosarcoma (review). Oncol Lett. 2018;16:6228–37. https://doi.org/10.3892/ol.2018.9434.CrossRefPubMedPubMedCentral

16.

Fujiwara T, Uotani K, Yoshida A, Morita T, Nezu Y, Kobayashi E, et al. Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma. Oncotarget. 2017;8:33375–92. https://doi.org/10.18632/oncotarget.16498.CrossRefPubMedPubMedCentral

17.

Li N, Luo D, Hu X, Luo W, Lei G, Wang Q, et al. RUNX2 and osteosarcoma. Anti Cancer Agents Med Chem. 2015;15:881–7.CrossRef

18.

van der Deen M, Taipaleenmäki H, Zhang Y, Teplyuk NM, Gupta A, Cinghu S, et al. MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem. 2013;288:21307–19. https://doi.org/10.1074/jbc.M112.445890.CrossRefPubMedPubMedCentral

19.

Zhang R, Yan S, Wang J, Deng F, Guo Y, Li Y, et al. MiR-30a regulates the proliferation, migration, and invasion of human osteosarcoma by targeting Runx2. Tumor Biol. 2016;37:3479–88. https://doi.org/10.1007/s13277-015-4086-7.CrossRef

20.

Broustas CG, Gokhale PC, Rahman A, Dritschilo A, Ahmad I, Kasid U. BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner. J Biol Chem. 2004;279:26780–8. https://doi.org/10.1074/jbc.M400159200.CrossRefPubMed

21.

WANG W, ZHANG L, ZHENG K, ZHANG X. miR-17-5p promotes the growth of osteosarcoma in a BRCC2-dependent mechanism. Oncol Rep. 2016;35:1473–82. https://doi.org/10.3892/or.2016.4542.CrossRefPubMed

22.

MA C, ZHAN C, YUAN H, CUI Y, ZHANG Z. MicroRNA-603 functions as an oncogene by suppressing BRCC2 protein translation in osteosarcoma. Oncol Rep. 2016;35:3257–64. https://doi.org/10.3892/or.2016.4718.CrossRefPubMed

23.

Liao Y-Y, Tsai H-C, Chou P-Y, Wang S-W, Chen H-T, Lin Y-M, et al. CCL3 promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in human osteosarcoma cells. Oncotarget. 2016;7:4310–25. https://doi.org/10.18632/oncotarget.6708.CrossRefPubMed

24.

XU E, ZHAO J, MA J, WANG C, ZHANG C, JIANG H, et al. miR-146b-5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by targeting zinc and ring finger 3. Oncol Rep. 2016;35:275–83. https://doi.org/10.3892/or.2015.4393.CrossRefPubMed

25.

Sun X, Dai G, Yu L, Hu Q, Chen J, Guo W. miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2. Sci Rep. 2018;8:606. https://doi.org/10.1038/s41598-017-18739-3.CrossRefPubMedPubMedCentral

26.

Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015;6(6):5022–40. https://doi.org/10.18632/oncotarget.3217.CrossRefPubMed

27.

Zhu Y, Tang L, Zhao S, Sun B, Cheng L, Tang Y, et al. CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613. Cancer Sci. 2018;109:2412–22. https://doi.org/10.1111/cas.13653.CrossRefPubMedPubMedCentral

28.

Georges S, Calleja LR, Jacques C, Lavaud M, Moukengue B, Lecanda F, et al. Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma. Oncotarget. 2018;9:35726–41. https://doi.org/10.18632/oncotarget.26284.CrossRefPubMedPubMedCentral

29.

•• Lu J, Song G, Tang Q, Yin J, Zou C, Zhao Z, et al. MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1. Oncogene. 2017;36:231–41. https://doi.org/10.1038/onc.2016.194 Describes the role of miR-26a as tumor suppressor in osteosarcoma stem cells. MiR-26a targets Jagged1 and inhibits osteosarcoma cell growth by attenuating Jagged1/Notch signaling. In patients, reduced miR-26a is associated with metastases and poor survival . CrossRefPubMed

30.

Waning DL, Guise TA. Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res. 2014;20:3071–7. https://doi.org/10.1158/1078-0432.CCR-13-1590.CrossRefPubMedPubMedCentral

31.

Coleman RE. Impact of bone-targeted treatments on skeletal morbidity and survival in breast cancer. Oncology (Williston Park). 2016;30:695–702.

32.

D’Oronzo S, Brown J, Coleman R. The value of biomarkers in bone metastasis. Eur J Cancer Care (Engl). 2017;26:e12725. https://doi.org/10.1111/ecc.12725.CrossRef

33.

Browne G, Taipaleenmäki H, Stein GS, Stein JL, Lian JB. MicroRNAs in the control of metastatic bone disease. Trends Endocrinol Metab. 2014;25:320–7. https://doi.org/10.1016/j.tem.2014.03.014.CrossRefPubMedPubMedCentral

34.

•• Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang T-C, et al. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2014;512:431–5. https://doi.org/10.1038/nature13375 This study identified miR-34a as an important regulator of osteoclast function. Overexpression of pharmacological delivery of miR-34a attenuates bone metastases by targeting a novel pro-osteoclastogenic molecule Tgif2. CrossRefPubMed

35.

Taipaleenmäki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL, et al. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 2015;75:1433–44. https://doi.org/10.1158/0008-5472.CAN-14-1026.CrossRefPubMedPubMedCentral

36.

Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabières C, et al. miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes. Cancer Res. 2018;78:5259–73. https://doi.org/10.1158/0008-5472.CAN-17-3058.CrossRefPubMed

37.

Johnson RW, Merkel AR, Page JM, Ruppender NS, Guelcher SA, Sterling JA. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis. 2014;31:945–59. https://doi.org/10.1007/s10585-014-9682-1.CrossRefPubMedPubMedCentral

38.

Taipaleenmäki H, Farina NH, van Wijnen AJ, Stein JL, Hesse E, Stein GS, et al. Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget. 2016;7:79032–46. https://doi.org/10.18632/oncotarget.12593.CrossRefPubMedPubMedCentral

39.

Liu X, Cao M, Palomares M, Wu X, Li A, Yan W, et al. Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res. 2018;20:127. https://doi.org/10.1186/s13058-018-1059-y.CrossRefPubMedPubMedCentral

40.

Johnstone CN, Chand A, Putoczki TL, Ernst M. Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer. Cytokine Growth Factor Rev. 2015;26:489–98. https://doi.org/10.1016/j.cytogfr.2015.07.015.CrossRefPubMed

41.

McCoy EM, Hong H, Pruitt HC, Feng X. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells. BMC Cancer. 2013;13:16. https://doi.org/10.1186/1471-2407-13-16.CrossRefPubMedPubMedCentral

42.

Cai W-L, Huang W-D, Li B, Chen T-R, Li Z-X, Zhao C-L, et al. microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. Mol Cancer. 2018;17:9. https://doi.org/10.1186/s12943-017-0746-0.CrossRefPubMedPubMedCentral

43.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442.CrossRefPubMed

44.

Fornetti J, Welm AL, Stewart SA. Understanding the bone in cancer metastasis. J Bone Miner Res. 2018;33:2099–113. https://doi.org/10.1002/jbmr.3618.CrossRefPubMed

45.

Bonci D, Coppola V, Patrizii M, Addario A, Cannistraci A, Francescangeli F, et al. A microRNA code for prostate cancer metastasis. Oncogene. 2016;35:1180–92. https://doi.org/10.1038/onc.2015.176.CrossRefPubMed

46.

Huang S, Wa Q, Pan J, Peng X, Ren D, Huang Y, et al. Downregulation of miR-141-3p promotes bone metastasis via activating NF-κB signaling in prostate cancer. J Exp Clin Cancer Res. 2017;36:173. https://doi.org/10.1186/s13046-017-0645-7.CrossRefPubMedPubMedCentral

47.

Wa Q, Li L, Lin H, Peng X, Ren D, Huang Y, et al. Downregulation of miR-19a-3p promotes invasion, migration and bone metastasis via activating TGF-β signaling in prostate cancer. Oncol Rep. 2017;39:81–90. https://doi.org/10.3892/or.2017.6096.CrossRefPubMedPubMedCentral

48.

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018;20:69–84. https://doi.org/10.1038/s41580-018-0080-4.CrossRef

49.

Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell. 2018;24:65–78. https://doi.org/10.1016/j.stem.2018.11.011.CrossRefPubMedPubMedCentral

50.

Chen J, Yan D, Wu W, Zhu J, Ye W, Shu Q. MicroRNA-130a promotes the metastasis and epithelial-mesenchymal transition of osteosarcoma by targeting PTEN. Oncol Rep. 2016;35:3285–92. https://doi.org/10.3892/or.2016.4719.CrossRefPubMed

51.

Nazeri E, Gouran Savadkoohi M, Majidzadeh-A K, Esmaeili R. Chondrosarcoma: an overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets. Crit Rev Oncol Hematol. 2018;131:102–9. https://doi.org/10.1016/j.critrevonc.2018.09.001.CrossRefPubMed

52.

Wu M-H, Huang P-H, Hsieh M, Tsai C-H, Chen H-T, Tang C-H. Endothelin-1 promotes epithelial&#x2013;mesenchymal transition in human chondrosarcoma cells by repressing miR-300. Oncotarget. 2016;7:70232–46. https://doi.org/10.18632/oncotarget.11835.CrossRefPubMedPubMedCentral

53.

Wu M-H, Huang C-Y, Lin J-A, Wang S-W, Peng C-Y, Cheng H-C, et al. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells. Oncogene. 2014;33:1725–35. https://doi.org/10.1038/onc.2013.109.CrossRefPubMed

54.

Ahmadi A, Najafi M, Farhood B, Mortezaee K. Transforming growth factor-β signaling: tumorigenesis and targeting for cancer therapy. J Cell Physiol. 2018. https://doi.org/10.1002/jcp.27955.

55.

Miyazawa K, Miyazono K. Regulation of TGF-β family signaling by inhibitory Smads. Cold Spring Harb Perspect Biol. 2017;9:a022095. https://doi.org/10.1101/cshperspect.a022095.CrossRefPubMedPubMedCentral

56.

•• Yu J, Lei R, Zhuang X, Li X, Li G, Lev S, et al. MicroRNA-182 targets SMAD7 to potentiate TGFβ-induced epithelial-mesenchymal transition and metastasis of cancer cells. Nat Commun. 2016;7:13884. https://doi.org/10.1038/ncomms13884 Describes that TGF-β increases the expression of miR-182, which suppresses SMAD7 protein. Since SMAD7 is a TGF-β antagonist, this mechanism disables the auto inhibition of TGF-β signaling and potentiates TGF-β-induced EMT and cancer cell invasion. CrossRefPubMedPubMedCentral

Titel: MicroRNAs in Bone Metastasis
verfasst von: Eric Hesse
Hanna Taipaleenmäki
Publikationsdatum: 23.03.2019
Verlag: Springer US
Erschienen in: Current Osteoporosis Reports / Ausgabe 3/2019
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-019-00510-4

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

MicroRNAs in Bone Metastasis

Abstract

Purpose of Review

Recent Findings

Summary

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

A Second Career for Chondrocytes—Transformation into Osteoblasts

Nuclear Fibroblast Growth Factor Receptor Signaling in Skeletal Development and Disease

The Osteocyte as a Novel Key Player in Understanding Periodontitis Through its Expression of RANKL and Sclerostin: a Review

Pro-inflammatory Cytokines and Osteocytes

Falls and Fractures in Diabetes—More than Bone Fragility

Inter-site Variability of the Human Osteocyte Lacunar Network: Implications for Bone Quality

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

Update Orthopädie und Unfallchirurgie